Search results for "PRI"

showing 10 items of 17196 documents

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases

2018

Background: No data is available on the molecular background of the extra-nodal extension (ENE) of lymph node metastasis (LN) in colorectal cancer (CRC). Methods: A series of 22 ENE-positive CRCs was considered and three samples per case were selected (the primary CRC, an ENE-negative and an ENE-positive metastatic LN). Samples (n=66) were analysed by immunohistochemistry for PD-L1, CD4, CD8, CD68 and CD80. Fifteen out of twenty-two cases were further profiled through a hotspot multigene mutational custom panel, including 164 hotspot regions of AKT1, APC, BRAF, CTNNB1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, PTEN and TP53 genes. Results: A significantly higher percentage of CD4-, CD8- and CD68-pos…

0301 basic medicineNeuroblastoma RAS viral oncogene homologCancer ResearchColorectal cancerBiomarkers; Colorectal cancer; Extranodal extension; Metastasis; Oncology; Genetics; Cancer ResearchPDGFRAmedicine.disease_causelcsh:RC254-282not knownMetastasisMetastasis03 medical and health sciences0302 clinical medicineExtranodal extensionGeneticsmedicinePTENlcsh:QH573-671Biomarkers; Colorectal cancer; Extranodal extension; Metastasisneoplasmsbiologybusiness.industrylcsh:Cytologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrimary tumorColorectal cancerdigestive system diseases030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinCancer researchImmunohistochemistryKRASbusinessPrimary ResearchBiomarkersCancer Cell International
researchProduct

The Volatilomic Footprints of Human HGC-27 and CLS-145 Gastric Cancer Cell Lines

2021

The presence of certain volatile biomarkers in the breath of patients with gastric cancer has been reported by several studies; however, the origin of these compounds remains controversial. In vitro studies, involving gastric cancer cells may address this problem and aid in revealing the biochemical pathways underlying the production and metabolism of gastric cancer volatile indicators. Gas chromatography with mass spectrometric detection, coupled with headspace needle trap extraction as the pre-concentration technique, has been applied to map the volatilomic footprints of human HGC-27 and CLS-145 gastric cancer cell lines and normal Human Stomach Epithelial Cells (HSEC). In total, 27 volat…

0301 basic medicineNonanalEthyl acetateHexanalBiochemistry Genetics and Molecular Biology (miscellaneous)Biochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinevolatile organic compoundsMolecular Bioscienceslcsh:QH301-705.5Molecular BiologyOriginal ResearchChemistrygastric cancerMetabolismCLS-145HGC-27Heptanal030104 developmental biologychemical footprintBiochemistrylcsh:Biology (General)Cell culture030220 oncology & carcinogenesisCancer cellGas chromatography–mass spectrometryGC-MSFrontiers in Molecular Biosciences
researchProduct

Perinatal nutrition: How to take care of the gut microbiota?

2016

Perinatal and postnatal nutritional environments can result in long-lasting and/or permanent consequences that may increase the risk of chronic diseases in adulthood. The impact of perinatal nutrition on infant microbiome development has been increasingly gaining interest, however scarce information can be found about nutrition on maternal microbiome. The infant microbiome plays an essential role in human health and its assembly is determined by maternal offspring exchanges of microbiota. Microbial colonization runs in parallel with the immune system maturation and has a decisive role in intestinal physiology and regulation. This process is adversely affected by several practices, including…

0301 basic medicineOffspringEndocrinology Diabetes and Metabolismmedicine.medical_treatmentIntestinal physiologylcsh:TX341-641Gut floraPerinatal03 medical and health sciences0302 clinical medicineEnvironmental healthmedicineLactationCaesarean section030212 general & internal medicineMicrobiomeNutrition2. Zero hungerNutrition and DieteticsbiologyNutritional statusbiology.organism_classificationPerinatal nutrition3. Good health030104 developmental biologyInfant formulaImmunologyMode of deliveryMicrobiomelcsh:Nutrition. Foods and food supplyClinical Nutrition Experimental
researchProduct

Archaeology and ichnology at Gombore II-2, Melka Kunture, Ethiopia: everyday life of a mixed age hominin group 700,000 years ago

2018

AbstractWe report the occurrence at 0.7 million years (Ma) of an ichnological assemblage at Gombore II-2, which is one of several archaeological sites at Melka Kunture in the upper Awash Valley of Ethiopia, 2000 m asl. Adults and children potentially as young as 12 months old left tracks in a silty substrate on the shore of a body of water where ungulates, as well as other mammals and birds, congregated. Furthermore, the same layers contain a rich archaeological and palaeontological record, confirming that knapping was taking place in situ and that stone tools were used for butchering hippo carcasses at the site. The site gives direct information on hominin landscape use at 0.7 Ma and may p…

0301 basic medicineOld Left010506 paleontologySciencegrowthtanzanialengthEnvironment01 natural sciencesArticlemultidisciplinary; growth; foot; children; site; footprints; tanzania; height; length; tracks; kenya; ethiopia03 medical and health sciencesIchnologychildrenGroup (stratigraphy)siteAssemblage (archaeology)AnimalsHumansEveryday lifeHistory Ancient0105 earth and related environmental sciencesShoregeography.geographical_feature_categoryKnappingFossilsQRPaleontologyHominidae15. Life on landfootprintstracksArchaeology030104 developmental biologyGeographykenyaArchaeologyfootMedicineethiopiamultidisciplinaryheight
researchProduct

Olfactory system in mammals: structural and functional anatomy

2016

Olfactory system in mammals: structural and functional anatomy

0301 basic medicineOlfactory systemanatomy[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionanimal diseasesmammalOlfactionBiology03 medical and health sciencesPrimary olfactory cortex0302 clinical medicineparasitic diseasesmedicinereproductive and urinary physiologyOlfactory receptorfungiAnatomyolfactoryOlfactory bulb[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030104 developmental biologymedicine.anatomical_structurecortexFunctional anatomyepitheliumOlfactory epithelium[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgery
researchProduct

Identification of accessory olfactory system and medial amygdala in the zebrafish

2017

AbstractZebrafish larvae imprint on visual and olfactory cues of their kin on day 5 and 6 postfertilization, respectively. Only imprinted (but not non-imprinted) larvae show strongly activated crypt (and some microvillous) cells demonstrated by pERK levels after subsequent exposure to kin odor. Here, we investigate the olfactory bulb of zebrafish larvae for activated neurons located at the sole glomerulus mdG2 which receives crypt cell input. Imprinted larvae show a significantly increased activation of olfactory bulb cells compared to non-imprinted larvae after exposure to kin odor. Surprisingly, pERK activated Orthopedia-positive cell numbers in the intermediate ventral telencephalic nucl…

0301 basic medicineOlfactory systemanimal structuresGene ExpressionSensory systemImprinting PsychologicalAmygdalaArticleOlfactory Receptor Neurons03 medical and health sciences0302 clinical medicinemedicineAnimalsPhosphorylationZebrafishZebrafishFluorescent DyesGlomerulus (olfaction)Microscopy ConfocalMitogen-Activated Protein Kinase 3MultidisciplinarybiologyfungiOlfactory PathwaysCarbocyaninesZebrafish ProteinsAmygdalabiology.organism_classificationOlfactory BulbOlfactory bulbCell biologySmell030104 developmental biologymedicine.anatomical_structureOdorHypothalamusLarvaOdorants030217 neurology & neurosurgeryTranscription FactorsScientific Reports
researchProduct

mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience.

2018

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. Patients and Methods: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. Results: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months wit…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSingle CenterGeneral Biochemistry Genetics and Molecular BiologyTyrosine-kinase inhibitorTargeted therapylaw.invention03 medical and health sciences0302 clinical medicineRisk groupsRandomized controlled trialRenal cell carcinomalawRisk FactorsInternal medicineGermanymedicineOverall survivalHumansMolecular Targeted TherapyNeoplasm MetastasisSurvival rateCarcinoma Renal CellProtein Kinase InhibitorsAgedRandomized Controlled Trials as TopicRetrospective StudiesPharmacologybusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisFemalebusinessResearch ArticleIn vivo (Athens, Greece)
researchProduct

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French P…

2016

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Cote d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan–Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8–53.8%] versus 44.5…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsDiseaseKaplan-Meier EstimateMetastasis03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineEpidemiologyInternal MedicinemedicineHumansRegistriesskin and connective tissue diseaseseducationSurvival rateAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisSurgeryFemaleFrancebusinessThe breast journal
researchProduct

Response: Methods for second primary cancers evaluation have to be standardized

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Endometrial cancerCancerSecond primary cancermedicine.diseaseSecond Primary CancersCancer registry03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineEpidemiology of cancermedicineEtiologybusinessInternational Journal of Cancer
researchProduct

Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab…

2020

Abstract Background: Neoantigens arising from somatic mutations are attractive targets for cancer immunotherapy as they may be recognized as foreign by the immune system. RO7198457, a systemically administered RNA-Lipoplex iNeST was designed to stimulate T cell responses against neoantigens. A first-in-human Phase Ib study of RO7198457, in combination with the aPD-L1 antibody atezolizumab is being conducted in patients with locally advanced or metastatic solid tumors. Methods: RO7198457 is manufactured on a per-patient basis and contains up to 20 tumor-specific neoepitopes. Nine doses of RO7198457 were administered i.v. in weekly and bi-weekly intervals during the 12-week induction stage an…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMelanomaMedizinLocally advancedSpecific immunotherapyCancermedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCancer immunotherapyAtezolizumab030220 oncology & carcinogenesisInternal medicinemedicinePrior ImmunotherapyIn patientbusinessCancer Research
researchProduct